Clinical trials: Liraglutide
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2…
- Trial name
- LIRA-Ramadan™ (NCT01917656)
- Testing
- liraglutide, metformin, sulphonylurea
- Where
- 41 sites in Algeria, India and 5 more
- Volunteers
- 343 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled…
- Trial name
- DUAL™IV (NCT01618162)
- Testing
- insulin degludec/liraglutide
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Diabete Type 2
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05268237
- Testing
- Liraglutide
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Biolingus
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers
This trial is conducted in Japan. The aim of this trial is to assess the safety and tolerability of NNC 90-1170 (liraglutide) in healthy Japanese male subjects.
- Trial name
- NCT01620463
- Testing
- liraglutide
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus Type 2
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct…
- Trial name
- NCT02205528
- Testing
- Liraglutide, Metformin, NNC0090-2746
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in…
- Trial name
- NCT01733758
- Testing
- Albiglutide 30 mg weekly, Albiglutide 50 mg weekly, Liraglutide 0.9 mg daily
- Where
- 74 sites in Japan
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
Diabetes, Healthy
To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood concentration of liraglutide (pharmacokinetics) as well as the effects on glucose and insulin (pharmacodynamics) after 21 days of daily…
- Trial name
- NCT00761540
- Testing
- liraglutide
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
- Trial name
- NCT02461589
- Testing
- semaglutide, liraglutide
- Where
- 150 sites in United States, Austria and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
Obesity
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
The study is investigating the use of Saxenda (liragltuide 3.0 milligrams (mg) once daily) for weight management. The primary objective is to investigate the change in body weight after initiation and use of Saxenda ® according…
- Trial name
- INSPIRE Turkey (NCT05438186)
- Testing
- Liraglutide
- Where
- Turkey (Türkiye)
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.
- Trial name
- NCT06439056
- Testing
- NEX-22A, a prolonged release formulation of liraglutide
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Nanexa AB
Diabetes, Diabetes Mellitus, Type 2
Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.
- Trial name
- NCT01821846
- Testing
- liraglutide
- Where
- 7 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone…
- Trial name
- NCT02235961
- Testing
- NNC9204-0530, liraglutide
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes…
- Trial name
- NCT02420262
- Testing
- insulin degludec/liraglutide, insulin glargine, insulin aspart
- Where
- 117 sites in United States, Argentina and 10 more
- Volunteers
- 506 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes.
- Trial name
- LEAD-3 (NCT00294723)
- Testing
- liraglutide, glimepiride
- Where
- 117 sites in United States, Mexico and 1 more
- Volunteers
- 746 people
- Sponsor
- Novo Nordisk A/S
Knee Osteoarthritis, Synovitis of Knee
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: patients between…
- Trial name
- INFLAM MOTION (NCT07225829)
- Testing
- 4P004
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 130 people
- Sponsor
- 4Moving Biotech
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus
Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)
This study will evaluate the safety, efficacy, and pharmacokinetics of MK-8521 given once daily compared to placebo and another diabetes drug in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01982630
- Testing
- MK-8521, Liraglutide
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Primary Objective: The primary objective of this study was to assess the dose-response relationship of SAR425899 versus placebo in terms of glycemic control as measured by the change in glycosylated hemoglobin (HbA1c).
- Trial name
- NCT02973321
- Testing
- SAR425899, Liraglutide, Metformin
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi